Deciphera Pharmaceuticals

This #Thanksgiving, we're grateful for the opportunity to improve the lives of people living with cancer and make a difference in the communities where we live and work. We’re especially thankful to our Deciphera team for their unwavering dedication to this mission. Happy Thanksgiving! #TheDecipheraDifference

This Veterans Day, we honor the courageous contributions of our U.S. Veterans. For the second year in a row, Deciphera’s employee-led Culture group donated over 100 lbs. of Halloween candy to Treats for Troops, a campaign that collects candy for service members to provide extra comfort to the Veteran community in a unique and fun way during the autumn season. Thank you to all who serve. #TreatsForTroops

This week is Invisible Disabilities Week, an important time to recognize and raise awareness for people with conditions that aren’t always apparent. Many of those living with Tenosynovial Giant Cell Tumor (#TGCT) experience pain and other issues that may not be seen from the outside. Learn more about this disease here: https://www.tgcttruth.com/ #InvisibleDisabilitiesWeek

#DidYouKnow Tenosynovial Giant Cell Tumor (TGCT) is a rare, locally aggressive neoplasm, also known as a tumor. People living with these tumors often experience pain and stiffness, impaired physical function and limited range of motion. While surgery may help, these tumors can recur. Learn more about this disease: https://www.tgcttruth.com/

September 30 is #RareCancerDay. Help National Organization for Rare Disorders and the Rare Cancer Coalition raise awareness for rare cancers like #GIST. Visit https://bit.ly/RCD-23 to learn more about how to get involved.

On #WorldCancerResearchDay, we celebrate the tremendous progress that has been made in the fight against cancer, thanks to the unwavering dedication of researchers across the globe, but recognize there is still more work to be done. Let’s keep pushing the boundaries to improve the lives of people living with #cancer. 

Today Deciphera, a member of ONO Pharma, announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for vimseltinib for priority review. Read more: https://bit.ly/3WZ4PgQ

Deciphera employees recognized #SarcomaAwarenessMonth and #GISTAwarenessDay this year by participating in group activities, including a #sarcoma research fundraising walk, to raise awareness and education for these complex cancers. We’re proud of our team for showing their continued commitment to our mission to discover, develop, and deliver important new medicines to patients for the treatment of cancer. Learn more about the Deciphera difference: https://lnkd.in/eVxsxaq7 #GIST #CureSarcoma

Today Deciphera, a member of ONO Pharma, announced that the marketing authorization application (MAA) for vimseltinib was accepted for review by the European Medicines Agency (EMA.) Read more: https://bit.ly/3W9OHYb #ONOPHARMA

Today is #GISTAwarenessDay, a chance for patients, caregivers, doctors and others in the #GIST community to raise awareness for people living with this rare sarcoma. Each one of us at Deciphera is united in our mission to discover, develop and deliver medicines to patients for the treatment of cancers like GIST. Learn more: https://bit.ly/3Q1W8i7